On August 10, 2026, the U.S. Department of Justice (DOJ) announced that Veloxis Pharmaceuticals, Inc., a North Carolina-based drug manufacturer, agreed to pay over $46 million to resolve criminal and civil allegations that it paid healthcare professionals (HCPs) kickbacks in the form of lavish meals, alcohol, luxury trips, and payments to induce prescriptions of Envarsus XR, its kidney transplant immunosuppression drug.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Maura Friedlander
Fifth Circuit Adopts Narrow Interpretation Of Two Critical DEA Regulations
Ilene Albala’s articles from Goodwin Procter LLP are most popular: within Food, Drugs, Healthcare and Life Sciences topic(s) in United States Goodwin Procter LLP are most popular: within Criminal Law, Immigration and Cannabis & Hemp topic(s) On February 13, 2026, the Fifth Circuit issued a unanimous panel opinion holding that the Drug Enforcement Agency ("DEA") misinterpreted two of its pivotal regulations — its "corresponding responsibility" (21 C.F.R. § 1306.04(a)) and "usual course of...
Fifth Circuit Adopts Narrow Interpretation of Two Critical DEA Regulations | JD Supra
On February 13, 2026, the Fifth Circuit issued a unanimous panel opinion holding that the Drug Enforcement Agency (“DEA”) misinterpreted two of its pivotal regulations — its “corresponding responsibility” (21 C.F.R. § 1306.04(a)) and “usual course of professional practice” (21 C.F.R. § 1306.06) regulations.1 The Fifth Circuit took a narrow view of both regulations in an opinion that rejected the DEA’s own longstanding interpretation of these regulations, which has been deferred to by other...
Historic False Claims Act Enforcement Illustrates Trump Administration’s Focus on Healthcare Fraud | JD Supra
False Claims Act enforcement reached yet another record high in 2025. On January 16, 2026, the U.S. Department of Justice (“DOJ”) announced that settlements and judgments under the False Claims Act (“FCA”) reached a record-breaking $6.8 billion in Fiscal Year 2025. This is more than twice the amount of FCA settlements and judgments in FY 2024, around $2.9 billion. Relators brought 1,297 qui tam lawsuits in FY 2025, also an all-time high and a big increase over FY 2024’s 979 qui tams.
DOJ Renews Focus on Private Equity Amid Record False Claims Act Enforcement | JD Supra
2023 was another record year for False Claims Act enforcement. On February 22, 2024, the U.S. Department of Justice (DOJ) announced that the federal government and whistleblowers were party to a record number of FCA settlements and judgments in Fiscal Year 2023. Of the $2.68 billion recovered, more than $1.8 billion related to matters involving the healthcare industry.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Maura
Contact Maura, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack